Affiliation:
1. Faculty of Medicine, Institute of Pathology, University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany
Abstract
MET tyrosine kinase receptor pathway activation has become an important actionable target in solid tumors. Aberrations in the MET proto-oncogene, including MET overexpression, the activation of MET mutations, MET mutations that lead to MET exon 14 skipping, MET gene amplifications, and MET fusions, are known to be primary and secondary oncogenic drivers in cancer; these aberrations have evolved as predictive biomarkers in clinical diagnostics. Thus, the detection of all known MET aberrations in daily clinical care is essential. In this review, current molecular technologies for the detection of the different MET aberrations are highlighted, including the benefits and drawbacks. In the future, another focus will be on the standardization of detection technologies for the delivery of reliable, quick, and affordable tests in clinical molecular diagnostics.
Reference82 articles.
1. Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges;Fujino;Lung Cancer,2021
2. MET and Small-Cell Lung Cancer;Gelsomino;Cancers,2014
3. MET-dependent solid tumours-molecular diagnosis and targeted therapy;Guo;Nat. Rev. Clin. Oncol.,2020
4. MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies;Lee;Expert Opin. Targets,2021
5. Jørgensen, J.T., and Mollerup, J. (2022). Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC. Cancers, 14.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献